GLP-1 Microdosing for Perimenopause: Hype, Help, or Something in Between?

Lifestyle |
Perimenopause |
4 min read

Published

June 15, 2026

Medically reviewed by

Alyssa Dweck MS, MD, FACOG, MSCP, Chief Medical Officer

Around one in eight Americans report using a glucagon-like peptide-1 (GLP-1) agonist medication, a type of trending prescription drug that may help improve blood sugar and manage weight.^1,2

Now, research is being published about GLP-1s for weight loss during perimenopause and menopause, specifically via microdosing.^3,4 Bonafide Chief Medical Officer, Dr. Alyssa Dweck, explains what GLP-1 microdosing is and the pros vs. cons of using GLP-1s in perimenopause.

What Is GLP-1 Microdosing?

Research suggests that postmenopausal women have 20% higher total fat than women who are yet to enter menopause.⁵ So that begs the answer to the question, “is GLP-1 microdosing an option to maintain a healthy weight in perimenopause?”

While GLP-1 popularity in brands like Ozempic has surged, with benefits being tied to the FDA-recommended dosages, researchers have documented growing interest in GLP-1 microdosing—a term that may describe two distinct practices:⁶

Standard, physician-guided dose adjustments
Off-label use of GLP-1 drugs at doses lower than those the FDA recommends

The idea, publications explain, is for individuals to reap the benefits of GLP-1s with reduced side effects, which may include:⁷

Nausea
Vomiting
Diarrhea
Headache

Experts believe the concept of GLP-1 microdosing may have stemmed from obesity drug shortages in 2021 and 2022.⁸ The Cleveland Clinic clarifies that while adjusting GLP-1 dosages is a common, safe practice for healthcare providers and patients under their strict supervision, microdosing compounded versions of GLP-1s—which are not FDA-approved—is a different practice with its own potential safety and quality risks.⁹

Microdosing GLP-1 Benefits

Your healthcare provider may talk you through some of the positives of microdosing GLP-1s, which could include benefits such as:¹⁰

Decreased cost (per dose)
Less side effects
Longer availability

GLP-1 Microdosing Pros vs. Cons

As with any prescription medication, there are also pros and cons to consider before starting use. Microdosing GLP1-s may come with the following pros and cons: ^11,12

GLP-1 Microdosing Benefits	GLP-1 Microdosing Risks
Reduced side effects	Lower effectiveness
Reduced costs	Safety risks (with compounded versions)
Decreased appetite	Slower results

Can a GLP-1 Help with Weight Loss in Perimenopause?

According to Dr. Dweck, emerging studies suggest GLP-1s can be a valuable option for weight loss in perimenopause, particularly for those taking hormone therapy¹³—and potentially even more effective in women than in men at any age.^14,15

“A 2025 review addressing GLP-1 use for weight loss in perimenopausal, and menopausal women concluded that GLP1 drugs are a consistent and valuable pharmacologic agent for weight loss,” explains Dr. Dweck. “In addition, a 2026 systematic review found that GLP-1 medications produce greater weight loss in women than men, potentially due to the synergy between GLP-1 drugs and estrogens.”

However, Dr. Dweck emphasizes that the few studies that exist are relatively new— and there’s still a lot to learn about how GLP-1s may benefit women in midlife.

“More research is needed in the perimenopause population to further assess risks and benefits,” she says.

Who Is a Candidate for GLP-1 Microdosing in Perimenopause?

According to Dr. Dweck, many women in perimenopause who meet the standard FDA-approved indications might be ideal candidates for GLP-1 medications. Those indications include:¹⁶

● A body mass index (BMI) over 30
● A BMI over 27 with at least one weight-related comorbidity:
- Type 2 diabetes
- High blood pressure
- High cholesterol
- Obstructive sleep apnea
- Cardiovascular disease
- MASH (metabolic dysfunction-associated steatohepatitis), a type of liver inflammation

GLP-1 for Menopause Weight Gain: What Research Says About Microdosing

Dr. Dweck cautions that research on GLP-1 dosing for women in perimenopause is slim and ongoing. She also reiterates that there’s much more to learn about microdosing—especially when carried out without the guidance of a medical professional.¹⁷

“GLP-1 drugs are effective for weight management, including in perimenopausal women, based on general population data,” she explains. “But perimenopause-specific dosing, efficacy, or safety data is lacking. While ‘microdosing’ is a common, colloquially-used term, specifics on

reduced frequency and/or dosing after initial weight loss is still emerging.”

The Bottom Line on Microdosing GLP-1s

Research on GLP-1s for weight loss is, overall, promising.¹⁷ However, scientists are just beginning to dive into GLP-1 use for weight loss in perimenopause, meaning research is still in the early stages. If you’re wondering if you’re a candidate for GLP-1s, it’s best to reach out to a trusted healthcare provider, who can answer any questions you may have about suggested medications or proper dosing.

TITLE TAG: GLP-1 Microdosing for Perimenopause: Benefits & Risks | Bonafide

Resources